BioPharm Company Tonix Breaks Ground on New Bedford R&D Facility

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. has broken ground on a 45,000-square-foot clinical scale manufacturing facility at the New Bedford Business Park in Massachusetts.

The new facility is expected to house Tonix’s Advanced Development Center (ADC) for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including COVID-19. Tonix expects the facility to be operational in the first half of 2022.

“The South Coast is fast becoming a significant player in biotech in Massachusetts, and Tonix Pharmaceuticals’ decision to open the Advanced Development Center within the New Bedford Business Park is a positive indicator of future economic growth throughout the region,” said Bill Keating, Congressman for Massachusetts’s 9th congressional district. “Tonix Pharmaceuticals is bringing good jobs to our region, and I look forward to watching their growth as the local economy continues to benefit from increased investment on the South Coast, including in South Coast Rail. The research, development, and manufacturing planned to take place in the new ADC has the potential to improve lives all over the world, and that is something we can all be proud of.”